Bioxytran, INC 8-K filings

Bioxytran announced encouraging clinical observations in the first patient treated with PLICID, a novel galectin antagonist for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), showing functional improvements without adverse events.

Bioxytran, Inc. announced the completion of a $1.2 million private placement to fund working capital and advance development programs.

Bioxytran, Inc. modified its Convertible Preferred Stock conversion terms and awarded 6 million shares of Preferred Stock to CEO David Platt for commercial and capital funding efforts.

Bioxytran, Inc. announced positive Phase 1b/2a clinical study results for its broad-range antiviral drug, ProLectin-M, in mild to moderate COVID-19 patients.

Bioxytran, Inc. announced a commercial distribution agreement with Khoury Medical LTD for its A-SUQAR dietary supplement, marking a transition to commercial revenue.

Bioxytran, Inc. announced positive Phase 2 clinical trial results for ProLectin-M, demonstrating complete viral load elimination in 100% of treated patients by Day 7 compared to placebo.

Bioxytran, Inc. announced the termination of Mike Sheikh as an Officer, with Sheikh contesting the dismissal's reason and its impact on severance.

Bioxytran, Inc. announced the immediate resignation of a director and Audit Committee Chair due to disagreements over corporate governance practices.

Bioxytran, Inc. has acquired NDPD Pharma, Inc. in a stock transaction, gaining access to key assets including preferred stock, a COVID-19-related license agreement, and patents for antiviral treatments.

Bioxytran, Inc. announces a $1.6 million investment from Triton Funds LP to settle debt, fund clinical trials, and for working capital, while management forfeits over $460,000 in accrued compensation.

Bioxytran, Inc. restated its financial statements for 2022 and 2023 due to errors in share valuation and other accounting inconsistencies, following the disqualification of its previous auditor.

Bioxytran's new preprint suggests that modulating galectin-3 could significantly improve the effectiveness of immunotherapy drugs in cancer treatment.

Bioxytran, Inc. has acquired NDPD Pharma, Inc. in a stock transaction valued at $15.85 million, gaining control of patents for a promising antiviral compound.

Bioxytran issued convertible preferred stock to insiders in exchange for common stock and debt, and announced a press release regarding research on carbon monoxide's impact on brain function.

Bioxytran has partnered with the Heme Foundation and NDPD Pharma to develop a Universal Oxygen Carrier (UOC) as a blood transfusion alternative, with the Heme Foundation initially contributing up to $10 million.

Bioxytran announces that its BXT-25 drug is expected to act as a universal oxygen carrier, similar to hyperbaric oxygenation, for stroke and Alzheimer's patients, with its efficacy monitored by an FDA-approved device.

Bioxytran Inc. has replaced its independent auditor, BF Borgers CPA PC, with Fruci & Associates II, PLLC, effective May 7, 2024.

Bioxytran, Inc. has designated 49.5 million shares of convertible preferred stock and appointed Dr. Radka Milanova to its Board of Directors, effective April 19, 2024.